about
Mutations and polymorphisms in hemoglobin genes and the risk of pulmonary hypertension and death in sickle cell diseaseInterferon-gamma induces p11 gene and protein expression in human epithelial cells through interferon-gamma-activated sequences in the p11 promoterHemoglobin and the paracrine and endocrine functions of nitric oxideEpidermal growth factor induces p11 gene and protein expression and down-regulates calcium ionophore-induced arachidonic acid release in human epithelial cellsMetabolic Syndrome and the LungMechanisms of nitrite bioactivationNitrite reductase activity of cytochrome cOxidases and peroxidases in cardiovascular and lung disease: new concepts in reactive oxygen species signalingNitrite signaling in pulmonary hypertension: mechanisms of bioactivation, signaling, and therapeuticsGlobin X is a six-coordinate globin that reduces nitrite to nitric oxide in fish red blood cellsNitrite reductase activity of nonsymbiotic hemoglobins from Arabidopsis thalianaGenetic determinants of haemolysis in sickle cell anaemia.Cardiovascular complications and risk of death in sickle-cell disease.Updated clinical classification of pulmonary hypertension.Isolated right ventricular dysfunction in patients with human immunodeficiency virus.Pulmonary complications of sickle cell disease.Pulmonary arterial hypertension: the clinical syndrome.Angiogenic and inflammatory markers of cardiopulmonary changes in children and adolescents with sickle cell disease.Chronic hyper-hemolysis in sickle cell anemia: association of vascular complications and mortality with less frequent vasoocclusive painCrises in Sickle Cell Disease.A pilot study of electronic directly observed therapy to improve hydroxyurea adherence in pediatric patients with sickle-cell disease.Characterization of whole blood gene expression profiles as a sequel to globin mRNA reduction in patients with sickle cell disease.Establishment of a transgenic sickle-cell mouse model to study the pathophysiology of priapism.Risk factors for mortality in adult patients with sickle cell disease: a meta-analysis of studies in North America and Europe.Potential therapeutic action of nitrite in sickle cell diseaseNitrate and nitrite in biology, nutrition and therapeuticsCytoprotective effects of nitrite during in vivo ischemia-reperfusion of the heart and liverSegmentation and quantification of pulmonary artery for noninvasive CT assessment of sickle cell secondary pulmonary hypertension.Computed tomography correlates with cardiopulmonary hemodynamics in pulmonary hypertension in adults with sickle cell disease.Cellular, pharmacological, and biophysical evaluation of explanted lungs from a patient with sickle cell disease and severe pulmonary arterial hypertensionRisk factors for death in 632 patients with sickle cell disease in the United States and United KingdomPulmonary hypertension in hemolytic disorders: pulmonary vascular disease: the global perspective.Enzymatic function of hemoglobin as a nitrite reductase that produces NO under allosteric control.Pulmonary hypertension: NHLBI Workshop on the Primary Prevention of Chronic Lung Diseases.Nitric oxide scavenging by red blood cell microparticles and cell-free hemoglobin as a mechanism for the red cell storage lesion.Association of G6PD with lower haemoglobin concentration but not increased haemolysis in patients with sickle cell anaemia.NT-proBNP as a marker of cardiopulmonary status in sickle cell anaemia in AfricaExercise capacity and haemodynamics in patients with sickle cell disease with pulmonary hypertension treated with bosentan: results of the ASSET studies.Elevated N-terminal pro-brain natriuretic peptide is associated with mortality in tobacco smokers independent of airflow obstruction.Hydroxyurea-induced expression of glutathione peroxidase 1 in red blood cells of individuals with sickle cell anemia
P50
Q24606163-7A683751-8548-4195-AE61-6E8C2894064BQ28184631-4E10FE9E-33EF-4360-A24F-54C629F6C430Q28190068-D6E7DF7C-FB52-4387-868C-A49F3CA0639DQ28217028-D10A44EC-79B4-433E-B34F-DFF094B20994Q28384152-97EA41AB-5C1C-4A4A-88F4-7A199405BB0BQ28384653-60724C66-65F1-4780-9F6E-2DC48A033DACQ28386250-10D260BF-1D24-4698-9E89-934DB65DF14AQ28393242-C66DA87E-5A56-4E6E-8AAF-B19ACFC4C654Q28396562-18A5D886-DABA-41DA-A6AE-11766F73690BQ28595571-47167BC2-E5AA-483B-B122-7CFEE4D9A656Q28661211-02525C0C-3469-4E6D-93DE-C31AC6137BE5Q29417116-240FBC22-C245-4EE3-B5B7-4C86824C3B58Q30249258-635C9566-9401-4C97-B490-FA7678FE4AE6Q30378433-85090973-343A-49B5-9E85-3F29032A5F70Q30410364-03D365D6-496F-404A-BCEC-4877B3F1514BQ30515769-88394707-D793-4D9D-AF4D-186E9570DC7DQ30583630-5D8D3A36-2A50-4D91-9B7F-A9D68F839D25Q30945205-588E8326-87D9-4785-BE92-2540A9C190C4Q33332124-E0EFC545-A6C3-45B7-B78D-C9E294C9CD58Q33429704-36B00A3E-3F3F-4B22-A376-0CC5AD36012DQ33440495-ECF74331-3F02-49B2-8572-4561A2ED3E14Q33489601-4DC2B80A-63E3-4AB9-96FE-44E845D643DBQ33572814-5C1C28AC-54CE-43DA-B364-052BC0CAF08FQ33574142-53FC58CB-93D3-4D0F-8A49-0ADAB2815436Q33681568-7B5AAFAB-C66A-44B7-A450-5DB1E635587AQ33685139-952CED3C-8523-4A9C-BD2C-C7F08451D102Q33743659-B6255619-6315-4398-A5BE-E650C7D8EE44Q33766843-00440CAB-7EE9-4172-8A7A-A871080E2C27Q33805998-44ABC570-2B8C-43A5-8711-BED51C292F13Q33806253-0C1795BE-B231-4FB2-A903-AD5CD74E755AQ33837174-C6BB38EF-C700-4F55-9F14-32290EEF7C47Q33899415-89250FD4-ED0E-4867-A46F-1783D1632C55Q33901706-CA06BAC7-C6A2-4352-9CB4-D0F1D5B364C8Q33956819-7BAD971A-6E15-42DE-85F1-8C9C023C16F4Q33957600-C9279FB1-CBB0-4B23-9E43-4A6A1E9982F6Q34005594-EDB5C93D-A587-4D90-9CFE-881CA0DD3F14Q34009129-525D1154-1DAC-4F4E-9AF3-5027925125ADQ34038886-78B8C79F-0350-4B1E-8BE7-35AD0F5EF2F2Q34075676-643DA9BF-5E17-4765-8FEF-D49489A28EC6Q34110079-7EFDAC70-2EFC-405C-B635-AC7518E3FC44
P50
description
Forscher
@de
chercheur
@fr
investigador
@es
researcher
@en
հետազոտող
@hy
研究者
@zh
name
Mark T Gladwin
@ast
Mark T Gladwin
@en
Mark T Gladwin
@es
Mark T Gladwin
@nl
type
label
Mark T Gladwin
@ast
Mark T Gladwin
@en
Mark T Gladwin
@es
Mark T Gladwin
@nl
prefLabel
Mark T Gladwin
@ast
Mark T Gladwin
@en
Mark T Gladwin
@es
Mark T Gladwin
@nl
P101
P21
P31
P496
0000-0001-7267-9006